Identification of drug-specific pathways based on gene expression data: application to drug induced lung injury.

  title={Identification of drug-specific pathways based on gene expression data: application to drug induced lung injury.},
  author={Ioannis N. Melas and Theodore Sakellaropoulos and Francesco Iorio and Leonidas G. Alexopoulos and Wei-Yin Loh and Douglas A. Lauffenburger and Julio S{\'a}ez-Rodr{\'i}guez and Jane P. F. Bai},
  journal={Integrative biology : quantitative biosciences from nano to macro},
  volume={7 8},
Identification of signaling pathways that are functional in a specific biological context is a major challenge in systems biology, and could be instrumental to the study of complex diseases and various aspects of drug discovery. Recent approaches have attempted to combine gene expression data with prior knowledge of protein connectivity in the form of a PPI network, and employ computational methods to identify subsets of the protein-protein-interaction (PPI) network that are functional, based… 

Figures and Tables from this paper

Contextualization of causal regulatory networks from toxicogenomics data applied to drug-induced liver injury

CARNIVAL, a causal network contextualisation tool, was applied to infer upstream regulatory signaling networks based on gene expression microarray data from the TG-GATEs database to infer potential pathology-inducing regulation among fibrosis-inducing compounds.

Tissue‐Specific Analysis of Pharmacological Pathways

A data‐driven method that integrates drug‐target relationships with gene expression, protein‐protein interaction, and pathway annotation data is introduced and provides a better understanding of the cellular response to drugs and can be applied to many research topics in systems pharmacology.

Using activation status of signaling pathways as mechanism-based biomarkers to predict drug sensitivity

A predictive framework is presented in which gene expression data are recoded into activity statuses of signal transduction circuits (sub-pathways within signaling pathways that connect receptor proteins to final effector proteins that trigger cell actions) which provide insight into drug molecular mechanisms of action.

A Computational Platform and Guide for Acceleration of Novel Medicines and Personalized Medicine.

The use of the most perturbed HLA genes to assess the safety risk for immune-mediated adverse reactions such as Stevens-Johnson syndrome/toxic epidermal necrolysis is described.

A Biologically-Based Computational Approach to Drug Repurposing for Anthrax Infection

A computational approach was utilized to score 474 drugs/compounds for their ability to reverse the toxic effects of anthrax toxins and found that Simvastatin and bepridil with reported in vitro potency for protecting cells from LT and ET toxicities were computationally ranked fourth and eighth.

Translational systems pharmacology‐based predictive assessment of drug‐induced cardiomyopathy

The ILP‐constructed signaling networks of drugs were better predictors than DEGs, and the microRNAs that reportedly regulate expression of the authors' six top predictors are of diagnostic value for natural heart failure or doxorubicin‐induced cardiomyopathy.

Qualitative modeling of signaling networks in replicative senescence by selecting optimal node and arc sets

A novel logic-based method for identifying signaling network by combining experimental data with prior knowledge about the connectivity of the involved proteins, which indicates that senescent cells are not responsive to insulin stimulation and activate pathways that are known to establish and maintain senescence.

SignaLink3: a multi-layered resource to uncover tissue-specific signaling networks

SignaLink3 is a value-added knowledge-base that provides manually curated data on signaling pathways and integrated data from several types of databases (interaction, regulation, localisation, disease, etc.) for humans, and three major animal model organisms.

PathFX provides mechanistic insights into drug efficacy and safety for regulatory review and therapeutic development

By discovering molecular interaction pathways, PathFX improved the understanding of drug associations to safety and efficacy phenotypes and may provide a new means to improve regulatory and therapeutic development decisions.



Creating and analyzing pathway and protein interaction compendia for modelling signal transduction networks

An ensemble network from multiple on-line sources representing a significant portion of all machine-readable and reconcilable human knowledge on proteins and protein interactions involved in inflammation is assembled, finding that the most widely used pathway databases are highly inconsistent with respect to the actual constituents and interactions in this network.

The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease

The first installment of a reference collection of gene-expression profiles from cultured human cells treated with bioactive small molecules is created, and it is demonstrated that this “Connectivity Map” resource can be used to find connections among small molecules sharing a mechanism of action, chemicals and physiological processes, and diseases and drugs.

A human functional protein interaction network and its application to cancer data analysis

A highly reliable functional interaction network upon expert-curated pathways is built and applied to the analysis of two genome-wide GBM and several other cancer data sets, suggesting common mechanisms in the cancer biology.

A novel signaling pathway impact analysis

A novel signaling pathway impact analysis (SPIA) that combines the evidence obtained from the classical enrichment analysis with a novel type of evidence, which measures the actual perturbation on a given pathway under a given condition.

Tissue-Specific Functional Networks for Prioritizing Phenotype and Disease Genes

A systems-level, tissue-specific scheme advances over traditional global integration and analyses and establishes a prototype to address the tissue- specific effects of genetic perturbations, diseases and drugs.

Causal Network Models for Predicting Compound Targets and Driving Pathways in Cancer

This approach can bridge transcriptional profiles to compound targets and driving pathways in cancer, and test several approaches to traversing network topology, and shows that a consensus minimum-rank score (SigNet) beat individual methods and could highly rank compound targets among all network nodes.

Expression2Kinases: mRNA profiling linked to multiple upstream regulatory layers

The X2K approach can advance the understanding of cell signaling and unravel drugs mechanisms of action by integrating chromatin immuno-precipitation data, protein-protein interactions and kinase-substrate phosphorylation reactions, and can better identify regulatory mechanisms upstream of genome-wide differences in gene expression.

SignaLink 2 – a signaling pathway resource with multi-layered regulatory networks

With SignaLink 2 as a single resource, users can effectively analyze signaling pathways, scaffold proteins, modifier enzymes, transcription factors and miRNAs that are important in the regulation of signaling processes.

Discovering causal signaling pathways through gene-expression patterns

This work identifies consistently regulated signature genes specific for signal transduction pathways from a panel of single-pathway perturbation experiments and uses an algorithm that detects overrepresentation of these signature genes in a gene group of interest to infer the signaling pathway responsible for regulation.